Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. [PDF]
Yoo HK +7 more
europepmc +1 more source
CT-P13: a safe and effective treatment for IBD [PDF]
openaire +1 more source
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. [PDF]
Sagami S +5 more
europepmc +1 more source
Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease [PDF]
Fiorino G +11 more
openaire +3 more sources
Biosimilar CT-P13 comparable to infliximab in active RA [PDF]
openaire +1 more source
Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. [PDF]
Krstic M +3 more
europepmc +1 more source
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease. [PDF]
Fathallah N +10 more
europepmc +1 more source
Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT). [PDF]
Marotte H +7 more
europepmc +1 more source
Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease. [PDF]
Nomaru R +15 more
europepmc +1 more source
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. [PDF]
Schreiber S +16 more
europepmc +1 more source

